Man, 51 years of age, type 1 diabetes for 32 years. Patient also has history of Class II obesity, CVA, MI and insulin resistance. Patient referred to Obesity Center for weight loss. A1c was 8.2%. Plan was to start Symlin. Symlin was added at 30mcg daily before dinner. I recommended he get a CGM. He did.

Dr. Altamash Shaikh talks with Diabetes in Control Associate Medical Editor Joy Pape at the 2016 AACE Meeting. In part 1 of this Exclusive Interview, Dr. Shaikh explains the current state of diabetes in India and the needs required to help this population to manage this condition.

In this week's Homerun Slides, the vital stats of patients on the placebo and empagliflozin 10- and 25-gram study.

Fuel homeostasis: The peptide hormone insulin is secreted from pancreatic beta cells, and exerts a broad spectrum of anabolic effects in multiple tissues. In response to a meal, insulin stimulates uptake and storage of carbohydrate, fat, and amino acids, while, at the same time, antagonizing the catabolism of these fuel reserves.

The ADA has announced their new Standards of Care for 2017 and they are taking a more global approach to A1C, CVD and hypoglycemia. When it comes to CVD, there is a bigger push to get patients to improve blood pressure levels. They recommend more widespread use of ARB’s and …

What do we need to tell our patients about preventing the risk for death?

Psychological health, access to care, expanded and personalized treatment options and the tracking of hypoglycemia emphasized.

New recommendation based on results from two large clinical trials for patients with diabetes and CVD.

Clinically significant hypoglycemia redefined, bariatric surgery renamed.

Guest Post by David Kliff, Diabetic Investor
Dexcom (NASDAQ: DXCM) received FDA approval for non-adjunctive claim.